$heff's $tation of $tocks & $olid DD

[RealGenius]

ACRX Real lesson lies in delineating simple catalyst v the complex. Many examples of solid drug programs who fail approval because of manufacturing defects or issues related to packaging. ACRX fail due to delivery device not the drug, right. Former APPA now Heron suffered the same issue, because they wanted a prepackaged format.
Companies whose candidate comes in a complex packaging format seem to fail at a higher rate, while the additional risk does not seem to earn additional gains.
Try to identify the simplist catalysts for a better chance of playing the risk correctly.